Schistosomal myeloradiculopathy due to Schistosoma mansoni: report on 23 cases

Schistosoma mansoni infection is likely to be responsible for a significant proportion of cases of myelopathy occurring in areas where schistosomiasis is endemic. The aim of this study is to describe the clinical, laboratory and therapeutic data of 23 patients with schistosomal myeloradiculopathy. The medical records of 23 patients with schistosomal myelopathy admitted to two general hospitals of Belo Horizonte (MG), in Brazil, from 1995 to 1999, were reviewed retrospectively. Seventeen patients were male (74%). The mean age for the whole group was 27 years. Lower limb weakness and associated lumbar and/or lower limb pain were reported by 20 patients (87%), and 16 (70%) were unable to walk. All individuals presented urinary retention and 19 (83%) complained of intestinal dysfunction. The treatment was based on the association of antischistosomal drugs and corticosteroids. Five patients (22%) presented a full response to treatment, 13 (57%) partial response without functional limitations and 4 (17%) partial improvement with limitations or no response. Three out of the 4 patients who stopped steroids before 45 days of treatment developed recurrence of the symptoms and signs of myelopathy. Our cases demonstrate the severe presentation of the disease and the data disclosed here suggest that treatment with steroids should be kept for months after clinical improvement.

Saved in:
Bibliographic Details
Main Authors: Nobre,Vandack, Silva,Luciana CS, Ribas,João G, Rayes,Abdunnabi, Serufo,JC, Lana-Peixoto,MA, Marinho,Rosana FZ, Lambertucci,JR
Format: Digital revista
Language:English
Published: Instituto Oswaldo Cruz, Ministério da Saúde 2001
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762001000900020
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0074-02762001000900020
record_format ojs
spelling oai:scielo:S0074-027620010009000202001-10-03Schistosomal myeloradiculopathy due to Schistosoma mansoni: report on 23 casesNobre,VandackSilva,Luciana CSRibas,João GRayes,AbdunnabiSerufo,JCLana-Peixoto,MAMarinho,Rosana FZLambertucci,JR schistosomiasis myelopathy neuroschistosomiasis myeloradiculopathy Schistosoma mansoni infection is likely to be responsible for a significant proportion of cases of myelopathy occurring in areas where schistosomiasis is endemic. The aim of this study is to describe the clinical, laboratory and therapeutic data of 23 patients with schistosomal myeloradiculopathy. The medical records of 23 patients with schistosomal myelopathy admitted to two general hospitals of Belo Horizonte (MG), in Brazil, from 1995 to 1999, were reviewed retrospectively. Seventeen patients were male (74%). The mean age for the whole group was 27 years. Lower limb weakness and associated lumbar and/or lower limb pain were reported by 20 patients (87%), and 16 (70%) were unable to walk. All individuals presented urinary retention and 19 (83%) complained of intestinal dysfunction. The treatment was based on the association of antischistosomal drugs and corticosteroids. Five patients (22%) presented a full response to treatment, 13 (57%) partial response without functional limitations and 4 (17%) partial improvement with limitations or no response. Three out of the 4 patients who stopped steroids before 45 days of treatment developed recurrence of the symptoms and signs of myelopathy. Our cases demonstrate the severe presentation of the disease and the data disclosed here suggest that treatment with steroids should be kept for months after clinical improvement.info:eu-repo/semantics/openAccessInstituto Oswaldo Cruz, Ministério da SaúdeMemórias do Instituto Oswaldo Cruz v.96 suppl.0 20012001-09-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762001000900020en10.1590/S0074-02762001000900020
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Nobre,Vandack
Silva,Luciana CS
Ribas,João G
Rayes,Abdunnabi
Serufo,JC
Lana-Peixoto,MA
Marinho,Rosana FZ
Lambertucci,JR
spellingShingle Nobre,Vandack
Silva,Luciana CS
Ribas,João G
Rayes,Abdunnabi
Serufo,JC
Lana-Peixoto,MA
Marinho,Rosana FZ
Lambertucci,JR
Schistosomal myeloradiculopathy due to Schistosoma mansoni: report on 23 cases
author_facet Nobre,Vandack
Silva,Luciana CS
Ribas,João G
Rayes,Abdunnabi
Serufo,JC
Lana-Peixoto,MA
Marinho,Rosana FZ
Lambertucci,JR
author_sort Nobre,Vandack
title Schistosomal myeloradiculopathy due to Schistosoma mansoni: report on 23 cases
title_short Schistosomal myeloradiculopathy due to Schistosoma mansoni: report on 23 cases
title_full Schistosomal myeloradiculopathy due to Schistosoma mansoni: report on 23 cases
title_fullStr Schistosomal myeloradiculopathy due to Schistosoma mansoni: report on 23 cases
title_full_unstemmed Schistosomal myeloradiculopathy due to Schistosoma mansoni: report on 23 cases
title_sort schistosomal myeloradiculopathy due to schistosoma mansoni: report on 23 cases
description Schistosoma mansoni infection is likely to be responsible for a significant proportion of cases of myelopathy occurring in areas where schistosomiasis is endemic. The aim of this study is to describe the clinical, laboratory and therapeutic data of 23 patients with schistosomal myeloradiculopathy. The medical records of 23 patients with schistosomal myelopathy admitted to two general hospitals of Belo Horizonte (MG), in Brazil, from 1995 to 1999, were reviewed retrospectively. Seventeen patients were male (74%). The mean age for the whole group was 27 years. Lower limb weakness and associated lumbar and/or lower limb pain were reported by 20 patients (87%), and 16 (70%) were unable to walk. All individuals presented urinary retention and 19 (83%) complained of intestinal dysfunction. The treatment was based on the association of antischistosomal drugs and corticosteroids. Five patients (22%) presented a full response to treatment, 13 (57%) partial response without functional limitations and 4 (17%) partial improvement with limitations or no response. Three out of the 4 patients who stopped steroids before 45 days of treatment developed recurrence of the symptoms and signs of myelopathy. Our cases demonstrate the severe presentation of the disease and the data disclosed here suggest that treatment with steroids should be kept for months after clinical improvement.
publisher Instituto Oswaldo Cruz, Ministério da Saúde
publishDate 2001
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762001000900020
work_keys_str_mv AT nobrevandack schistosomalmyeloradiculopathyduetoschistosomamansonireporton23cases
AT silvalucianacs schistosomalmyeloradiculopathyduetoschistosomamansonireporton23cases
AT ribasjoaog schistosomalmyeloradiculopathyduetoschistosomamansonireporton23cases
AT rayesabdunnabi schistosomalmyeloradiculopathyduetoschistosomamansonireporton23cases
AT serufojc schistosomalmyeloradiculopathyduetoschistosomamansonireporton23cases
AT lanapeixotoma schistosomalmyeloradiculopathyduetoschistosomamansonireporton23cases
AT marinhorosanafz schistosomalmyeloradiculopathyduetoschistosomamansonireporton23cases
AT lambertuccijr schistosomalmyeloradiculopathyduetoschistosomamansonireporton23cases
_version_ 1756383404060835840